PEG10 counteracts signaling pathways of TGF-β and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells.
Apoptosis Regulatory Proteins
Bone Morphogenetic Protein Receptors, Type I
/ metabolism
Bone Morphogenetic Proteins
/ metabolism
Bone Neoplasms
/ metabolism
Cell Line, Tumor
Cell Movement
Cell Proliferation
Chondrosarcoma
/ metabolism
DNA-Binding Proteins
Gene Silencing
Humans
Matrix Metalloproteinase 1
/ metabolism
Neoplasm Invasiveness
Phosphorylation
Proteins
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
RNA-Binding Proteins
Receptor, Transforming Growth Factor-beta Type I
/ metabolism
Signal Transduction
Transforming Growth Factor beta
/ metabolism
p38 Mitogen-Activated Protein Kinases
/ metabolism
AKT
BMP
Chondrosarcoma
PEG10
TGF-β
Journal
Journal of bone and mineral metabolism
ISSN: 1435-5604
Titre abrégé: J Bone Miner Metab
Pays: Japan
ID NLM: 9436705
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
26
02
2018
accepted:
25
07
2018
pubmed:
11
8
2018
medline:
22
6
2019
entrez:
11
8
2018
Statut:
ppublish
Résumé
Recently, we reported highly active transforming growth factor (TGF)-β and bone morphogenetic protein (BMP) signaling in human chondrosarcoma samples and concurrent downregulation of paternally expressed gene 10 (PEG10). PEG10 expression was suppressed by TGF-β signaling, and PEG10 interfered with the TGF-β and BMP-SMAD pathways in chondrosarcoma cells. However, the roles of PEG10 in bone tumors, including chondrosarcoma, remain unknown. Here, we report that PEG10 promotes SW1353 chondrosarcoma cell growth by preventing TGF-β1-mediated suppression. In contrast, PEG10 knockdown augments the TGF-β1-induced motility of SW1353 cells. Individually, TGF-β1 and PEG10 siRNA increase AKT phosphorylation, whereas an AKT inhibitor, MK2206, mitigates the effect of PEG10 silencing on cell migration. SW1353 cell invasion was enhanced by BMP-6, which was further increased by PEG10 silencing. The effect of siPEG10 was suppressed by inhibitors of matrix metalloproteinase (MMP). BMP-6 induced expression of MMP-1, -3, and -13, and PEG10 lentivirus or PEG10 siRNA downregulated or further upregulated these MMPs, respectively. PEG10 siRNA increased BMP-6-induced phosphorylation of p38 MAPK and AKT, whereas the p38 inhibitor SB203580 and MK2206 diminished SW1353 cell invasion by PEG10 siRNA. SB203580 and MK2206 impeded the enhancing effect of PEG10 siRNA on the BMP-6-induced expression of MMP-1, -3, and -13. Our findings suggest dual functions for PEG10: accelerating cell growth by suppressing TGF-β signaling and inhibiting cell motility and invasion by interfering with TGF-β and BMP signaling via the AKT and p38 pathways, respectively. Thus, PEG10 might be a molecular target for suppressing the aggressive phenotypes of chondrosarcoma cells.
Identifiants
pubmed: 30094509
doi: 10.1007/s00774-018-0946-8
pii: 10.1007/s00774-018-0946-8
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
Bone Morphogenetic Proteins
0
DNA-Binding Proteins
0
PEG10 protein, human
0
Proteins
0
RNA-Binding Proteins
0
Transforming Growth Factor beta
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Bone Morphogenetic Protein Receptors, Type I
EC 2.7.11.30
Receptor, Transforming Growth Factor-beta Type I
EC 2.7.11.30
Matrix Metalloproteinase 1
EC 3.4.24.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-454Subventions
Organisme : Japan Society for the Promotion of Science
ID : 15K10486
Organisme : Japan Society for the Promotion of Science
ID : 15K10410
Organisme : Japan Society for the Promotion of Science
ID : 16K10910
Organisme : Japan Society for the Promotion of Science
ID : 17K10972
Organisme : Japan Society for the Promotion of Science
ID : 17K10933
Organisme : Japan Society for the Promotion of Science
ID : 26462307
Organisme : Japan Society for the Promotion of Science
ID : 25462343
Références
J Biol Chem. 1999 Sep 17;274(38):27161-7
pubmed: 10480932
J Biol Chem. 2000 Nov 24;275(47):36803-10
pubmed: 10969078
Nucleic Acids Res. 2001 Oct 1;29(19):4079-88
pubmed: 11574691
Nat Genet. 2001 Oct;29(2):117-29
pubmed: 11586292
J Biol Chem. 2002 Jan 4;277(1):854-61
pubmed: 11689553
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Virchows Arch. 2002 May;440(5):491-7
pubmed: 12021923
J Biol Chem. 2002 Aug 30;277(35):32360-8
pubmed: 12060661
Mol Pharmacol. 2002 Jul;62(1):58-64
pubmed: 12065755
Sci STKE. 2002 Sep 24;2002(151):pe40
pubmed: 12297674
Cancer Res. 2003 Jun 15;63(12):3043-8
pubmed: 12810624
J Bone Joint Surg Am. 1963 Oct;45:1450-8
pubmed: 14069783
J Biol Chem. 2005 Mar 4;280(9):8482-93
pubmed: 15611116
Chem Biol. 2005 Feb;12(2):181-9
pubmed: 15734645
J Orthop Res. 2005 Nov;23(6):1467-74
pubmed: 15927440
Nat Genet. 2006 Jan;38(1):101-6
pubmed: 16341224
Cancer Res. 2006 Jan 15;66(2):665-72
pubmed: 16423995
Biochem Biophys Res Commun. 2006 Jul 28;346(2):379-85
pubmed: 16765318
Oncol Rep. 2007 Mar;17(3):549-56
pubmed: 17273732
Int J Cancer. 2007 Nov 1;121(9):1984-93
pubmed: 17621626
Biochem Pharmacol. 2008 Mar 15;75(6):1292-301
pubmed: 18191107
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
J Cell Physiol. 2008 Dec;217(3):846-55
pubmed: 18720410
Mol Biol Cell. 2008 Dec;19(12):5373-86
pubmed: 18843047
Bone. 2009 Feb;44(2):233-42
pubmed: 19038372
J Bone Joint Surg Am. 2009 May;91(5):1063-72
pubmed: 19411454
Biochem Pharmacol. 2010 Jan 15;79(2):209-17
pubmed: 19682436
J Biochem. 2010 Jan;147(1):35-51
pubmed: 19762341
Cancer Sci. 2010 Feb;101(2):306-12
pubmed: 20067465
Nat Rev Cancer. 2010 Jun;10(6):415-24
pubmed: 20495575
Int J Biochem Cell Biol. 2010 Nov;42(11):1802-7
pubmed: 20691279
Pathol Oncol Res. 2011 Dec;17(4):859-66
pubmed: 21455631
Med Sci Monit. 2011 Aug;17(8):RA177-190
pubmed: 21804475
J Cell Physiol. 2012 Aug;227(8):3016-26
pubmed: 21959927
BMC Cancer. 2012 Oct 22;12:488
pubmed: 23088614
Ann Oncol. 2013 Nov;24(11):2916-22
pubmed: 24099780
Arch Biochem Biophys. 2014 Nov 1;561:159-66
pubmed: 25046842
Oncol Rep. 2014 Nov;32(5):2159-67
pubmed: 25199998
PLoS One. 2014 Nov 12;9(11):e112636
pubmed: 25390068
Cancer Res Treat. 2015 Oct;47(4):844-52
pubmed: 25687862
Clin Exp Med. 2016 May;16(2):177-82
pubmed: 25864113
Cell Rep. 2015 Aug 11;12(6):922-36
pubmed: 26235627
Int J Oncol. 2016 May;48(5):1933-42
pubmed: 26934961
Oncol Rep. 2017 Jan;37(1):510-518
pubmed: 28004118
Semin Cancer Biol. 2018 Feb;48:70-77
pubmed: 28473255
Sci Rep. 2017 Oct 18;7(1):13494
pubmed: 29044189
Oncotarget. 2017 Aug 5;8(43):74567-74581
pubmed: 29088808
FEBS Lett. 1995 May 8;364(2):229-33
pubmed: 7750577
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9
pubmed: 7777546
J Clin Invest. 1994 Dec;94(6):2307-16
pubmed: 7989586
Nature. 1994 Sep 15;371(6494):257-61
pubmed: 8078588
J Biol Chem. 1997 Jan 24;272(4):2446-51
pubmed: 8999957
J Med Chem. 1998 Sep 10;41(19):3568-71
pubmed: 9733482